Judit Mészáros Joergensen

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Lorenzo Falchi, Fabrice Jardin, Corinne Haïoun et al. · Blood · 2023 · 20 citations

Medicine, Molecular Biology, Oncology +16

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Sureda Balarí et al. · Blood · 2023 · 18 citations · Full text

Medicine, Hematology, Pharmacology +13

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chávez, Loretta J. Nastoupil, Franck Morschhauser et al. · Blood · 2023 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +15

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Martin Hutchings, Anna Sureda, Francesc Bosch et al. · Blood · 2024 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R²-CHOP in subjects with previously untreated, high-risk DLBCL.

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil et al. · Journal of Clinical Oncology · 2019 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17